KR101799113B1 - 올리고머를 함유하는 치환된 방향족 트리아진 화합물 - Google Patents
올리고머를 함유하는 치환된 방향족 트리아진 화합물 Download PDFInfo
- Publication number
- KR101799113B1 KR101799113B1 KR1020117026044A KR20117026044A KR101799113B1 KR 101799113 B1 KR101799113 B1 KR 101799113B1 KR 1020117026044 A KR1020117026044 A KR 1020117026044A KR 20117026044 A KR20117026044 A KR 20117026044A KR 101799113 B1 KR101799113 B1 KR 101799113B1
- Authority
- KR
- South Korea
- Prior art keywords
- group
- oligomer
- alkyl
- substituted aromatic
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17793109P | 2009-05-13 | 2009-05-13 | |
| US61/177,931 | 2009-05-13 | ||
| PCT/US2010/034770 WO2010132691A1 (en) | 2009-05-13 | 2010-05-13 | Oligomer-containing substituted aromatic triazine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20120015311A KR20120015311A (ko) | 2012-02-21 |
| KR101799113B1 true KR101799113B1 (ko) | 2017-11-17 |
Family
ID=42557491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020117026044A Active KR101799113B1 (ko) | 2009-05-13 | 2010-05-13 | 올리고머를 함유하는 치환된 방향족 트리아진 화합물 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US8772479B2 (enExample) |
| EP (1) | EP2430003B1 (enExample) |
| JP (1) | JP5656980B2 (enExample) |
| KR (1) | KR101799113B1 (enExample) |
| CN (1) | CN102421763B (enExample) |
| AU (1) | AU2010248943B2 (enExample) |
| CA (1) | CA2760219C (enExample) |
| IL (1) | IL216314B (enExample) |
| MX (1) | MX2011012044A (enExample) |
| WO (1) | WO2010132691A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011012044A (es) | 2009-05-13 | 2011-12-14 | Nektar Therapeutics | Compuestos de triazina aromatica sustituida que contienen oligomeros. |
| WO2015092819A2 (en) * | 2013-12-21 | 2015-06-25 | Nektar Therapeutics (India) Pvt. Ltd. | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5- amine |
| JP6884703B2 (ja) | 2015-02-25 | 2021-06-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | 障害を治療するための5ht作動薬 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002043772A2 (en) * | 2000-11-30 | 2002-06-06 | Shearwater Corporation | Water-soluble polymer conjugates of triazine derivatives |
| WO2006027711A2 (en) * | 2004-08-26 | 2006-03-16 | Nicholas Piramal India Limited | Prodrugs and codrugs containing bio- cleavable disulfide linkers |
| WO2006047372A2 (en) * | 2004-10-25 | 2006-05-04 | Seradyn, Inc. | Lamotrigine analogs |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE49823B1 (en) | 1979-06-01 | 1985-12-25 | Wellcome Found | 1,2,4-triazine derivatives,process for preparing such compounds and pharmaceutical compositions containing them |
| US4810646A (en) | 1984-11-28 | 1989-03-07 | Massachusetts Institute Of Technology | Glucan compositions and process for preparation thereof |
| US5028703A (en) | 1988-03-11 | 1991-07-02 | Massachusetts Institute Of Technology | Glucan composition and process for preparation thereof |
| US4992540A (en) | 1984-11-28 | 1991-02-12 | Massachusetts Institute Of Technology | Glucan composition and process for preparation thereof |
| US5032401A (en) | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
| RS53279B (sr) | 2003-12-16 | 2014-08-29 | Nektar Therapeutics | Monodisperzne smeše pegilisanog naloksola |
| FR2869907B1 (fr) | 2004-05-05 | 2009-02-13 | Fabre Pierre Dermo Cosmetique | Derives dimeriques de 5,6-diphenyl-1,2,4-triazine et leurs utilisations |
| US7740861B2 (en) | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
| US7678551B2 (en) | 2004-10-25 | 2010-03-16 | Seradyn, Inc. | Immunoassays for lamotrigine |
| US20080044438A1 (en) | 2006-03-17 | 2008-02-21 | Ostroff Gary R | Yeast Cell Particles As Oral Delivery Vehicles For Antigens |
| MX2011012044A (es) | 2009-05-13 | 2011-12-14 | Nektar Therapeutics | Compuestos de triazina aromatica sustituida que contienen oligomeros. |
-
2010
- 2010-05-13 MX MX2011012044A patent/MX2011012044A/es active IP Right Grant
- 2010-05-13 WO PCT/US2010/034770 patent/WO2010132691A1/en not_active Ceased
- 2010-05-13 CN CN201080020581.5A patent/CN102421763B/zh active Active
- 2010-05-13 EP EP10721887.7A patent/EP2430003B1/en active Active
- 2010-05-13 JP JP2012511017A patent/JP5656980B2/ja active Active
- 2010-05-13 KR KR1020117026044A patent/KR101799113B1/ko active Active
- 2010-05-13 AU AU2010248943A patent/AU2010248943B2/en active Active
- 2010-05-13 CA CA2760219A patent/CA2760219C/en active Active
- 2010-05-13 US US13/319,824 patent/US8772479B2/en active Active
-
2011
- 2011-11-10 IL IL216314A patent/IL216314B/en active IP Right Grant
-
2014
- 2014-05-20 US US14/282,732 patent/US8895553B2/en active Active
- 2014-10-30 US US14/528,444 patent/US9266845B2/en active Active
-
2016
- 2016-01-15 US US14/996,801 patent/US9617228B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002043772A2 (en) * | 2000-11-30 | 2002-06-06 | Shearwater Corporation | Water-soluble polymer conjugates of triazine derivatives |
| WO2006027711A2 (en) * | 2004-08-26 | 2006-03-16 | Nicholas Piramal India Limited | Prodrugs and codrugs containing bio- cleavable disulfide linkers |
| WO2006047372A2 (en) * | 2004-10-25 | 2006-05-04 | Seradyn, Inc. | Lamotrigine analogs |
Non-Patent Citations (1)
| Title |
|---|
| Justyna Ławecka 외 3명. Tetrahedron Letters. Vol. 49, 2008년, pp. 723-726* |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102421763B (zh) | 2015-06-17 |
| EP2430003A1 (en) | 2012-03-21 |
| KR20120015311A (ko) | 2012-02-21 |
| US20140256732A1 (en) | 2014-09-11 |
| CA2760219C (en) | 2016-08-16 |
| US20150065706A1 (en) | 2015-03-05 |
| CA2760219A1 (en) | 2010-11-18 |
| AU2010248943B2 (en) | 2015-05-21 |
| IL216314A0 (en) | 2012-01-31 |
| MX2011012044A (es) | 2011-12-14 |
| EP2430003B1 (en) | 2019-02-27 |
| US9266845B2 (en) | 2016-02-23 |
| JP5656980B2 (ja) | 2015-01-21 |
| AU2010248943A1 (en) | 2011-11-10 |
| US20160194294A1 (en) | 2016-07-07 |
| IL216314B (en) | 2018-05-31 |
| CN102421763A (zh) | 2012-04-18 |
| US9617228B2 (en) | 2017-04-11 |
| US8772479B2 (en) | 2014-07-08 |
| JP2012526847A (ja) | 2012-11-01 |
| US8895553B2 (en) | 2014-11-25 |
| US20120122871A1 (en) | 2012-05-17 |
| WO2010132691A1 (en) | 2010-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101561707B1 (ko) | 올리고머―항히스타민제 컨주게이트 | |
| WO2012083153A1 (en) | Oligomer-containing apremilast moiety compounds | |
| US9399033B2 (en) | Oligomer-containing pyrrolidine compounds | |
| US10265411B2 (en) | N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides | |
| KR101799113B1 (ko) | 올리고머를 함유하는 치환된 방향족 트리아진 화합물 | |
| WO2009054916A2 (en) | Oligomer conjugates of lidocaine and its derivatives | |
| JP6265998B2 (ja) | オリゴマー含有ベンズアミド系化合物 | |
| US9540330B2 (en) | Oligomer-containing hydantoin compounds | |
| EP2400989B1 (en) | Gabapentin-peg conjugates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| AMND | Amendment | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PX0901 | Re-examination |
St.27 status event code: A-2-3-E10-E12-rex-PX0901 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| PX0701 | Decision of registration after re-examination |
St.27 status event code: A-3-4-F10-F13-rex-PX0701 |
|
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 8 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 9 |